International Assets Investment Management LLC Acquires New Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

International Assets Investment Management LLC bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the fourth quarter, HoldingsChannel reports. The firm bought 37,315 shares of the biotechnology company’s stock, valued at approximately $3,598,000.

Several other hedge funds have also recently bought and sold shares of the stock. Barclays PLC grew its holdings in shares of BioMarin Pharmaceutical by 31.6% during the third quarter. Barclays PLC now owns 5,573,157 shares of the biotechnology company’s stock worth $493,111,000 after buying an additional 1,336,886 shares in the last quarter. Ameriprise Financial Inc. grew its stake in shares of BioMarin Pharmaceutical by 5.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,163,949 shares of the biotechnology company’s stock worth $456,906,000 after acquiring an additional 275,436 shares in the last quarter. Fort Washington Investment Advisors Inc. OH raised its holdings in shares of BioMarin Pharmaceutical by 10.7% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 1,308,245 shares of the biotechnology company’s stock valued at $115,754,000 after purchasing an additional 126,680 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of BioMarin Pharmaceutical by 2.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,304,797 shares of the biotechnology company’s stock valued at $115,448,000 after purchasing an additional 33,592 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of BioMarin Pharmaceutical by 3.7% in the third quarter. Northern Trust Corp now owns 1,219,814 shares of the biotechnology company’s stock worth $107,929,000 after purchasing an additional 43,695 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Trading Down 0.1 %

BMRN opened at $81.72 on Friday. The company has a quick ratio of 1.70, a current ratio of 2.74 and a debt-to-equity ratio of 0.12. BioMarin Pharmaceutical Inc. has a twelve month low of $76.02 and a twelve month high of $99.56. The stock has a market capitalization of $15.52 billion, a price-to-earnings ratio of 76.37, a P/E/G ratio of 1.30 and a beta of 0.34. The company has a 50-day simple moving average of $86.34 and a 200 day simple moving average of $88.92.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.05. BioMarin Pharmaceutical had a net margin of 8.31% and a return on equity of 5.34%. The business had revenue of $646.21 million for the quarter, compared to analyst estimates of $639.53 million. During the same quarter last year, the business posted $0.11 EPS. The firm’s revenue for the quarter was up 20.2% on a year-over-year basis. Analysts predict that BioMarin Pharmaceutical Inc. will post 1.98 EPS for the current fiscal year.

Insider Buying and Selling at BioMarin Pharmaceutical

In other news, Director Jean Jacques Bienaime sold 1,000 shares of the business’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $90.35, for a total transaction of $90,350.00. Following the completion of the transaction, the director now owns 562,203 shares of the company’s stock, valued at approximately $50,795,041.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other BioMarin Pharmaceutical news, insider Henry J. Fuchs sold 35,341 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $85.18, for a total value of $3,010,346.38. Following the sale, the insider now owns 212,117 shares in the company, valued at $18,068,126.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jean Jacques Bienaime sold 1,000 shares of the business’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $90.35, for a total transaction of $90,350.00. Following the sale, the director now directly owns 562,203 shares in the company, valued at approximately $50,795,041.05. The disclosure for this sale can be found here. In the last quarter, insiders have sold 90,079 shares of company stock valued at $7,896,036. 1.85% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BMRN. Cantor Fitzgerald reiterated an “overweight” rating and issued a $110.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, April 25th. Citigroup lowered their target price on BioMarin Pharmaceutical from $94.00 to $91.00 and set a “neutral” rating on the stock in a research report on Thursday, April 25th. Wells Fargo & Company increased their price target on BioMarin Pharmaceutical from $100.00 to $110.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $100.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, February 23rd. Finally, Scotiabank raised their target price on shares of BioMarin Pharmaceutical from $83.00 to $85.00 and gave the company a “sector perform” rating in a research note on Thursday, April 25th. Seven investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $107.50.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.